{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T14:25:51Z","timestamp":1758810351408,"version":"3.40.5"},"reference-count":58,"publisher":"Sociedade Brasileira de Pneumologia e Tisiologia","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Bras Pneumol."],"abstract":"<jats:p>Many interstitial lung diseases (ILDs) share mechanisms that result in a progressive fibrosing phenotype. In Brazil, the most common progressive fibrosing interstitial lung diseases (PF-ILDs) are chronic hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, unclassified ILD, and connective tissue diseases. PF-ILD is seen in approximately 30% of patients with ILD. Because PF-ILD is characterized by disease progression after initiation of appropriate treatment, a diagnosis of the disease resulting in fibrosis is critical. Different criteria have been proposed to define progressive disease, including worsening respiratory symptoms, lung function decline, and radiological evidence of disease progression. Although the time elapsed between diagnosis and progression varies, progression can occur at any time after diagnosis. Several factors indicate an increased risk of progression and death. In the last few years, antifibrotic drugs used in patients with idiopathic pulmonary fibrosis have been tested in patients with PF-ILD. The effects of nintedanib and placebo have been compared in patients with PF-ILD, a mean difference of 107.0 mL\/year being observed, favoring nintedanib. The U.S. Food and Drug Administration and the Brazilian Health Regulatory Agency have approved the use of nintedanib in such patients on the basis of this finding. Pirfenidone has been evaluated in patients with unclassified ILD and in patients with other ILDs, the results being similar to those for nintedanib. More studies are needed in order to identify markers of increased risk of progression in patients with ILD and determine the likelihood of response to treatment with standard or new drugs.<\/jats:p>","DOI":"10.36416\/1806-3756\/e20230098","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T16:59:07Z","timestamp":1690217947000},"page":"e20230098","source":"Crossref","is-referenced-by-count":2,"title":["Progressive fibrotic interstitial lung disease"],"prefix":"10.36416","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0352-9589","authenticated-orcid":false,"given":"Carlos","family":"A C Pereira1","sequence":"first","affiliation":[{"name":"1. Programa de Assist\u00eancia e Pesquisa em Doen\u00e7as Pulmonares Intersticiais, Departamento de Cl\u00ednica M\u00e9dica, Servi\u00e7o de Pneumologia, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4736-9043","authenticated-orcid":false,"given":"Soraya","family":"Cordero2","sequence":"additional","affiliation":[{"name":"2. Programa de P\u00f3s-Gradua\u00e7\u00e3o em Doen\u00e7as Pulmonares Intersticiais, Departamento de Cl\u00ednica M\u00e9dica, Servi\u00e7o de Pneumologia, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9250-3374","authenticated-orcid":false,"given":"Ana","family":"Carolina Resende2","sequence":"additional","affiliation":[{"name":"2. Programa de P\u00f3s-Gradua\u00e7\u00e3o em Doen\u00e7as Pulmonares Intersticiais, Departamento de Cl\u00ednica M\u00e9dica, Servi\u00e7o de Pneumologia, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22288","published-online":{"date-parts":[[2023,7,24]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1.            Lederer DJ, Martinez FJ. Idiopathic Pulmonary Fibrosis. N Engl J Med. 2018;378(19):1811-1823. https:\/\/doi.org\/10.1056\/NEJMra1705751","DOI":"10.1056\/nejmra1705751"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2.            Matias SLK. Relative frequency of incidental interstitial lung diseases in six centers in Brazil (thesis in Portuguese). S\u00e3o Paulo: Universidade Federal de S\u00e3o Paulo; 2022.","DOI":"10.33594\/000000072"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3.            Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019;381(18):1718-1727. https:\/\/doi.org\/10.1056\/NEJMoa1908681","DOI":"10.1056\/nejmoa1908681"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4.            Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18-e47. https:\/\/doi.org\/10.1164\/rccm.202202-0399ST","DOI":"10.1164\/rccm.1925erratum"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5.            Rajan SK, Cottin V, Dhar R, Danoff S, Flaherty KR, Brown KK, et al. Progressive pulmonary fibrosis: an expert group consensus statement. Eur Respir J. 2023;61(3):2103187. https:\/\/doi.org\/10.1183\/13993003.03187-2021","DOI":"10.1183\/13993003.03187-2021"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6.            Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968-1977. https:\/\/doi.org\/10.1056\/NEJMoa1113354","DOI":"10.1056\/nejmoa1113354"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7.            Wijsenbeek M, Cottin V. Spectrum of Fibrotic Lung Diseases. N Engl J Med. 2020;383(10):958-968. https:\/\/doi.org\/10.1056\/NEJMra2005230","DOI":"10.1056\/nejmra2005230"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8.            Valenzuela C, Cottin V. Epidemiology and real-life experience in progressive pulmonary fibrosis. Curr Opin Pulm Med. 2022;28(5):407-413. https:\/\/doi.org\/10.1097\/MCP.0000000000000908","DOI":"10.1097\/mcp.0000000000000908"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9.            George PM, Spagnolo P, Kreuter M, Altinisik G, Bonifazi M, Martinez FJ, et al. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir Med. 2020;8(9):925-934. https:\/\/doi.org\/10.1016\/S2213-2600(20)30355-6","DOI":"10.1016\/s2213-2600(20)30355-6"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10.          Ryerson CJ, Corte TJ, Lee JS, Richeldi L, Walsh SLF, Myers JL, et al. A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective. Am J Respir Crit Care Med. 2017;196(10):1249-1254. https:\/\/doi.org\/10.1164\/rccm.201702-0400PP","DOI":"10.1164\/rccm.201702-0400pp"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11.          Simpson T, Barratt SL, Beirne P, Chaudhuri N, Crawshaw A, Crowley LE, et al. The burden of progressive fibrotic interstitial lung disease across the UK. Eur Respir J. 2021;58(1):2100221. https:\/\/doi.org\/10.1183\/13993003.00221-2021","DOI":"10.1183\/13993003.00221-2021"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.          Kolb MR, Flaherty KR. The justification for the progressive fibrotic phenotype. Curr Opin Pulm Med. 2021;27(5):363-367. https:\/\/doi.org\/10.1097\/MCP.0000000000000803","DOI":"10.1097\/MCP.0000000000000803"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13.          Fukuda CY, Soares MR, de Castro Pereira CA. A score without diffusion capacity of the lung for carbon monoxide for estimating survival in idiopathic pulmonary fibrosis. Medicine (Baltimore). 2020;99(25):e20739. https:\/\/doi.org\/10.1097\/MD.0000000000020739","DOI":"10.1097\/md.0000000000020739"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14.          Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med. 2016;194(3):265-275. https:\/\/doi.org\/10.1164\/rccm.201604-0801CI","DOI":"10.1164\/rccm.201604-0801ci"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15.          Ryerson CJ, Cottin V, Brown KK, Collard HR. Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm. Eur Respir J. 2015;46(2):512-520. https:\/\/doi.org\/10.1183\/13993003.00419-2015","DOI":"10.1183\/13993003.00419-2015"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16.          Luppi F, Sebastiani M, Salvarani C, Bendstrup E, Manfredi A. Acute exacerbation of interstitial lung disease associated with rheumatic disease. Nat Rev Rheumatol. 2022;18(2):85-96. https:\/\/doi.org\/10.1038\/s41584-021-00721-z","DOI":"10.1038\/s41584-021-00721-z"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17.          Kang J, Kim YJ, Choe J, Chae EJ, Song JW. Acute exacerbation of fibrotic hypersensitivity pneumonitis: incidence and outcomes. Respir Res. 2021;22(1):152. https:\/\/doi.org\/10.1186\/s12931-021-01748-2","DOI":"10.1186\/s12931-021-01748-2"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18.          Khor YH, Gutman L, Abu Hussein N, Johannson KA, Glaspole IN, Guler SA, et al. Incidence and Prognostic Significance of Hypoxemia in Fibrotic Interstitial Lung Disease: An International Cohort Study. Chest. 2021;160(3):994-1005. https:\/\/doi.org\/10.1016\/j.chest.2021.04.037","DOI":"10.1016\/j.chest.2021.04.037"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19.          Walsh SLF, Devaraj A, Enghelmayer JI, Kishi K, Silva RS, Patel N, et al. Role of imaging in progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150):180073. https:\/\/doi.org\/10.1183\/16000617.0073-2018","DOI":"10.1183\/16000617.0073-2018"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20.          Egashira R, Raghu G. Quantitative computed tomography of the chest for fibrotic lung diseases: Prime time for its use in routine clinical practice?. Respirology. 2022;27(12):1008-1011. https:\/\/doi.org\/10.1111\/resp.14351","DOI":"10.1111\/resp.14351"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21.          Devaraj A, Milanese G, Sverzellati N. Thoracic computed tomography in the progressive fibrotic phenotype. Curr Opin Pulm Med. 2021;27(5):350-354. https:\/\/doi.org\/10.1097\/MCP.0000000000000804","DOI":"10.1097\/mcp.0000000000000804"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22.          Oldham JM, Lee CT, Wu Z, Bowman WS, Pugashetti JV, Dao N, et al. Lung function trajectory in progressive fibrosing interstitial lung disease. Eur Respir J. 2022;59(6):2101396. https:\/\/doi.org\/10.1183\/13993003.01396-2021","DOI":"10.1183\/13993003.01396-2021"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23.          Richeldi L, Ryerson CJ, Lee JS, Wolters PJ, Koth LL, Ley B, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax. 2012;67(5):407-411. https:\/\/doi.org\/10.1136\/thoraxjnl-2011-201184","DOI":"10.1136\/thoraxjnl-2011-201184"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24.          Pugashetti JV, Adegunsoye A, Wu Z, Lee CT, Srikrishnan A, Ghodrati S, et al. Validation of Proposed Criteria for Progressive Pulmonary Fibrosis. Am J Respir Crit Care Med. 2023;207(1):69-76. https:\/\/doi.org\/10.1164\/rccm.202201-0124OC","DOI":"10.1164\/rccm.202201-0124oc"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25.          Martinez FJ, Flaherty K. Pulmonary function testing in idiopathic interstitial pneumonias. Proc Am Thorac Soc. 2006;3(4):315-321. https:\/\/doi.org\/10.1513\/pats.200602-022TK","DOI":"10.1513\/pats.200602-022TK"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26.          Kolb M, Va\u0161\u00e1kov\u00e1 M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res. 2019;20(1):57. https:\/\/doi.org\/10.1186\/s12931-019-1022-1","DOI":"10.1186\/s12931-019-1022-1"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27.          Petnak T, Thongprayoon C, Baqir M, Ryu JH, Moua T. Antigen identification and avoidance on outcomes in fibrotic hypersensitivity pneumonitis. Eur Respir J. 2022;60(4):2101336. https:\/\/doi.org\/10.1183\/13993003.01336-2021","DOI":"10.1183\/13993003.01336-2021"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28.          Oh JH, Kang J, Song JW. Fibrosis score predicts mortality in patients with fibrotic hypersensitivity pneumonitis. Front Med (Lausanne). 2023;10:1131070. https:\/\/doi.org\/10.3389\/fmed.2023.1131070","DOI":"10.3389\/fmed.2023.1131070"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29.          Salisbury ML, Gu T, Murray S, Gross BH, Chughtai A, Sayyouh M, et al. Hypersensitivity Pneumonitis: Radiologic Phenotypes Are Associated With Distinct Survival Time and Pulmonary Function Trajectory. Chest. 2019;155(4):699-711. https:\/\/doi.org\/10.1016\/j.chest.2018.08.1076","DOI":"10.1016\/j.chest.2018.08.1076"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30.          Oliveira RK, Pereira CA, Ramos RP, Ferreira EV, Messina CM, Kuranishi LT, et al. A haemodynamic study of pulmonary hypertension in chronic hypersensitivity pneumonitis. Eur Respir J. 2014;44(2):415-424. https:\/\/doi.org\/10.1183\/09031936.00010414","DOI":"10.1183\/09031936.00010414"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31.          Creamer AW, Barratt SL. Prognostic factors in chronic hypersensitivity pneumonitis. Eur Respir Rev. 2020;29(156):190167. https:\/\/doi.org\/10.1183\/16000617.0167-2019","DOI":"10.1183\/16000617.0167-2019"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32.          Trushenko NV, Suvorova OA, Pershina ES, Nekludova GV, Chikina SY, Levina IA, et al. Predictors of Progression and Mortality in Patients with Chronic Hypersensitivity Pneumonitis: Retrospective Analysis of Registry of Fibrosing Interstitial Lung Diseases. Life (Basel). 2023;13(2):467. https:\/\/doi.org\/10.3390\/life13020467","DOI":"10.3390\/life13020467"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33.          Chiu YH, Koops MFM, Voortman M, van Es HW, Langezaal LCM, Welsing PMJ, et al. Prognostication of progressive pulmonary fibrosis in connective tissue disease-associated interstitial lung diseases: A cohort study. Front Med (Lausanne). 2023;10:1106560.","DOI":"10.3389\/fmed.2023.1106560"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"34.          Chen X, Guo J, Yu D, Jie B, Zhou Y. Predictors of Mortality in Progressive Fibrosing Interstitial Lung Diseases. Front Pharmacol. 2021;12:754851. https:\/\/doi.org\/10.3389\/fphar.2021.754851","DOI":"10.3389\/fphar.2021.754851"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"35.          Qiu M, Jiang J, Nian X, Wang Y, Yu P, Song J, et al. Factors associated with mortality in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis. Respir Res. 2021;22(1):264. https:\/\/doi.org\/10.1186\/s12931-021-01856-z","DOI":"10.1186\/s12931-021-01856-z"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36.          Le Gall A, Hoang-Thi TN, Porcher R, Dunogu\u00e9 B, Berezn\u00e9 A, Guillevin L, et al. Prognostic value of automated assessment of interstitial lung disease on CT in systemic sclerosis [published online ahead of print, 2023 Apr 19]. Rheumatology (Oxford). 2023;kead164. https:\/\/doi.org\/10.1093\/rheumatology\/kead164","DOI":"10.1093\/rheumatology\/kead164"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"37.          Campochiaro C, Hoffmann-Vold AM, Avouac J, Henes J, de Vries-Bouwstra J, Smith V, et al. Sex influence on outcomes of patients with systemic sclerosis-associated interstitial lung disease: a EUSTAR database analysis. Rheumatology (Oxford). 2023;62(7):2483-2491. https:\/\/doi.org\/10.1093\/rheumatology\/keac660","DOI":"10.1093\/rheumatology\/kead247"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38.          Cacciapaglia F, Air\u00f2 P, Fornaro M, Trerotoli P, De Lorenzis E, Corrado A, et al. Survival and prognostic factors from a multicentre large cohort of unselected Italian systemic sclerosis patients. Rheumatology (Oxford). 2023;62(4):1552-1558. https:\/\/doi.org\/10.1093\/rheumatology\/keac512","DOI":"10.1093\/rheumatology\/keac512"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"39.          de Oliveira Martins LV, Oliveira SM, Silvatti J, de Amorim FG, Agapito Tito CV, Kayser C. Mortality in Systemic Sclerosis-Associated Interstitial Lung Disease in Brazil: A Real-Life, Long-Term Follow-up Observational Study. J Clin Rheumatol. 2022;28(2):e532-e538. https:\/\/doi.org\/10.1097\/RHU.0000000000001792","DOI":"10.1097\/rhu.0000000000001792"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"40.          Zhou M, Jiang L, Nie L, Chen T, Zhang T, Sun W, et al. Myopathy is a Risk Factor for Poor Prognosis of Patients with Systemic Sclerosis: A retrospective cohort study. Medicine (Baltimore). 2020;99(33):e21734. https:\/\/doi.org\/10.1097\/MD.0000000000021734","DOI":"10.1097\/MD.0000000000021734"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"41.          Jeganathan N, Sathananthan M. Connective Tissue Disease-Related Interstitial Lung Disease: Prevalence, Patterns, Predictors, Prognosis, and Treatment. Lung. 2020;198(5):735-759. https:\/\/doi.org\/10.1007\/s00408-020-00383-w","DOI":"10.1007\/s00408-020-00383-w"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"42.          Wang Y, Guo Z, Ma R, Wang J, Wu N, Fan Y, et al. Prognostic Predictive Prognostic Predictive Characteristics in Patients With Fibrosing Interstitial Lung Disease: A Retrospective Cohort Study. Front Pharmacol. 2022;13:924754. https:\/\/doi.org\/10.3389\/fphar.2022.924754","DOI":"10.3389\/fphar.2022.924754"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"43.          Kuwana M, Gil-Vila A, Selva-O\u2019Callaghan A. Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders. Ther Adv Musculoskelet Dis. 2021;13:1759720X211032457. https:\/\/doi.org\/10.1177\/1759720X211032457","DOI":"10.1177\/1759720x211032457"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"44.          Kreuter M, Bendstrup E, Russell AM, Bajwah S, Lindell K, Adir Y, et al. Palliative care in interstitial lung disease: living well. Lancet Respir Med. 2017;5(12):968-980. https:\/\/doi.org\/10.1016\/S2213-2600(17)30383-1","DOI":"10.1016\/s2213-2600(17)30383-1"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"45.          Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020;8(5):453-460. https:\/\/doi.org\/10.1016\/S2213-2600(20)30036-9","DOI":"10.1055\/s-0039-3403297"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"46.          Flaherty KR, Wells AU, Cottin V, Devaraj A, Inoue Y, Richeldi L, et al. Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. Eur Respir J. 2022;59(3):2004538. https:\/\/doi.org\/10.1183\/13993003.04538-2020","DOI":"10.1183\/13993003.04538-2020"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"47.          Fern\u00e1ndez P\u00e9rez ER, Swigris JJ, Forss\u00e9n AV, Tourin O, Solomon JJ, Huie TJ, et al. Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis. Chest. 2013;144(5):1644-1651. https:\/\/doi.org\/10.1378\/chest.12-2685","DOI":"10.1378\/chest.12-2685"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"48.          Gimenez A, Storrer K, Kuranishi L, Soares MR, Ferreira RG, Pereira CAC. Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis. Thorax. 2018;73(4):391-392. https:\/\/doi.org\/10.1136\/thoraxjnl-2017-210035","DOI":"10.1136\/thoraxjnl-2017-210035"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"49.          Mullin ML, Churg A, Ryerson CJ. Management of fibrotic hypersensitivity pneumonitis. Curr Opin Pulm Med. 2022;28(5):421-431. https:\/\/doi.org\/10.1097\/MCP.0000000000000904","DOI":"10.1097\/mcp.0000000000000904"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"50.          Ejima M, Okamoto T, Suzuki T, Anzai T, Takahashi K, Miyazaki Y. Efficacy of treatment with corticosteroids for fibrotic hypersensitivity pneumonitis: a propensity score-matched cohort analysis. BMC Pulm Med. 2021;21(1):243. https:\/\/doi.org\/10.1186\/s12890-021-01608-1","DOI":"10.1186\/s12890-021-01608-1"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"51.          De Sadeleer LJ, Hermans F, De Dycker E, Yserbyt J, Verschakelen JA, Verbeken EK, et al. Impact of BAL lymphocytosis and presence of honeycombing on corticosteroid treatment effect in fibrotic hypersensitivity pneumonitis: a retrospective cohort study. Eur Respir J. 2020;55(4):1901983. https:\/\/doi.org\/10.1183\/13993003.01983-2019","DOI":"10.1183\/13993003.01983-2019"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"52.          Raimundo S, Pimenta AC, Cruz-Martins N, Rodrigues MC, Melo N, Mota PC, et al. Insights on chronic hypersensitivity pneumonitis\u2019 treatment: Factors associated with a favourable response to azathioprine. Life Sci. 2021;272:119274. https:\/\/doi.org\/10.1016\/j.lfs.2021.119274","DOI":"10.1016\/j.lfs.2021.119274"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"53.          Walsh SL, Sverzellati N, Devaraj A, Wells AU, Hansell DM. Chronic hypersensitivity pneumonitis: high resolution computed tomography patterns and pulmonary function indices as prognostic determinants. Eur Radiol. 2012;22(8):1672-1679. https:\/\/doi.org\/10.1007\/s00330-012-2427-0","DOI":"10.1007\/s00330-012-2427-0"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"54.          Wang P, Jones KD, Urisman A, Elicker BM, Urbania T, Johannson KA, et al. Pathologic Findings and Prognosis in a Large Prospective Cohort of Chronic Hypersensitivity Pneumonitis. Chest. 2017;152(3):502-509. https:\/\/doi.org\/10.1016\/j.chest.2017.02.011","DOI":"10.1016\/j.chest.2017.02.011"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"55.          Fern\u00e1ndez P\u00e9rez ER, Crooks JL, Lynch DA, Humphries SM, Koelsch TL, Swigris JJ, et al. Pirfenidone in fibrotic hypersensitivity pneumonitis: a double-blind, randomised clinical trial of efficacy and safety [published online ahead of print, 2023 Apr 7]. Thorax. 2023;thorax-2022-219795. https:\/\/doi.org\/10.1136\/thorax-2022-219795","DOI":"10.1136\/thorax-2022-219795"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"56.          Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020;8(2):147-157. https:\/\/doi.org\/10.1016\/S2213-2600(19)30341-8","DOI":"10.1016\/s2213-2600(19)30341-8"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"57.          Behr J, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, et al Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9(5):476-486. https:\/\/doi.org\/10.1016\/S2213-2600(20)30554-3","DOI":"10.1186\/s12890-017-0462-y"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"58.          Ghazipura M, Mammen MJ, Bissell BD, Macrea M, Herman DD, Hon SM, et al. Pirfeni-done in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Ann Am Thorac Soc. 2022;19(6):1030-1039. https:\/\/doi.org\/10.1513\/AnnalsATS.202103-342OC","DOI":"10.1513\/annalsats.202103-342oc"}],"container-title":["Jornal Brasileiro de Pneumologia"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T16:59:12Z","timestamp":1690217952000},"score":1,"resource":{"primary":{"URL":"https:\/\/jornaldepneumologia.com.br\/details\/3858\/en-US\/progressive-fibrotic-interstitial-lung-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,24]]},"references-count":58,"URL":"https:\/\/doi.org\/10.36416\/1806-3756\/e20230098","relation":{},"ISSN":["1806-3756"],"issn-type":[{"type":"electronic","value":"1806-3756"}],"subject":[],"published":{"date-parts":[[2023,7,24]]}}}